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To the Editor 
 
        The complement system is pivotal in protection against pathogens, but also plays important 
roles in bridging innate and adaptive immune responses (Scott and Botto, 2015) and in 
modulating local and systemic inflammation (Markiewski and Lambris, 2007). Activation of 
complement occurs through three different pathways (classical, alternative and lectin), 
converges at C3 cleavage and culminates in the formation of the membrane attack complex. 
The anaphylotoxic fragments, C3a and C5a, generated during the proteolytic cascade, recruit 
immune cells that can promote the removal of debris and pathogens, but can also cause tissue 
damage (Markiewski and Lambris, 2007).  
 
The main source of complement is the liver. However, locally produced complement, 
particularly C3, can modulate inflammation in a variety of organs. There is also evidence that 
not only immune cells such as macrophages and dendritic cells produce complement 
components, but also non-immune cells can contribute to local complement synthesis. In the 
skin keratinocytes are a potential source of C3 (Pasch et al., 2000). A role for C3 in the skin 
has been identified in UV-induced immune tolerance (Hammerberg et al., 1998) as well as in 
the protection against T cell mediated inflammation (Purwar et al., 2011). Furthermore, 
locally produced C3 contributes to the inflammatory responses accompanying wound healing 
(Rafail et al., 2014), an effect mediated mainly through C5a/C5aR interactions. The latter 
also play an important role in influencing the skin microbiome (Chehoud et al., 2013). In 
keeping with these observations in animal models, complement has been shown to have a 
role in the pathogenesis of many human skin diseases, including psoriasis (Kotnik V.,  2011). 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Psoriasis is an inflammatory skin disease characterised by epidermal hyperplasia, infiltration 
of immune cells and secretion of inflammatory cytokines (Tortola et al., 2012). The 
anaphylotoxic fragments, C3a and C5a, have been found in corneal scale extracts from 
psoriatic lesions (Takematsu et al., 1986). The C5a from these lesions has been shown to 
chemoattract monocyte-derived dendritic cells (Mrowietz et al., 2001), indicating that 
complement may contribute to the inflammatory process in this disease. In the inducible 
Activator Protein-1-dependent psoriasis-like mouse model the S100A8-S100A9 complex that 
promotes skin inflammation has been shown to upregulate C3 expression (Schonthaler et al., 
2013). Psoriasis-like dermatisis can be induced by topical application of the toll-like receptor 
7 (TLR7) agonist imiquimod (IMQ) (Van der Fits et al., 2009) in the form of Aldara® cream 
(Walter et al., 2013). Here we explore the role of complement in IMQ-mediated psoriasiform 
dermatitis.   
 
We first tested whether cutaneous IMQ treatment induces local C3 synthesis (experimental 
methods are provided as Supplementary information online) and found a progressive increase 
in C3 mRNA in the skin with repeated IMQ applications (Figure 1a and Figure S1a). 
Immunohistochemistry demonstrated that the C3 expression was predominantly in the dermis 
(Figure S1b). In vitro experiments with isolated dermal stromal cells (DSCs) showed that 
these cells can produce C3 upon stimulation with inflammatory cytokines known to be 
induced in IMQ-treated skin, but not upon direct challenge with a TLR7 agonist (Figure S1c). 
To test whether 3 contributes to the psoriatic-like lesions induced by IMQ, we then treated 
WT and C3-/- mice for 7 consecutive days. The treatment resulted in skin thickening, scaling 
and erythema (Figure 1b). However, mice lacking C3 displayed less skin inflammation with 
significantly reduced ear thickness and lower scores for erythema and scaling compared to 
WT mice (Figure 1c). Consistent with the reduced skin response in C3-/- mice, we found 
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significantly fewer infiltrating neutrophils, but slightly more monocytes, and no difference in 
the number of resident γδ T cells compared to WT animals (Figure 1d). IL-17 secretion by γδ 
T cells plays a key role in the IMQ-induced psoriasis model (van der Fits et al., 2009) and our 
data confirmed that IL-17 secretion was mainly restricted to these cells. Importantly, the 
frequency of IL-17-positive γδ T cells in both skin and draining LN was significantly lower 
in the absence of C3 (Figure 1e and 1f). All animals were handled in accordance with the 
institutional guidelines and the UK Home Office approved the procedures.  
 
We next evaluated whether C3 contributes to the local inflammatory response. To this end we 
analysed the gene expression of a selected number of cytokines/chemokines known to be 
induced in the skin by IMQ treatment (Di Meglio et al., 2014; Walter et al., 2013). At the 
peak of clinical inflammation on day 7, the C3-/- mice did not show any obvious differences 
in inflammatory gene-expression (Figure 2a). However, at the onset of the clinical pathology, 
day 3, when the cytokine/chemokine gene response peaks (Di Meglio et al., 2014), C3-
deficient mice had a markedly reduced response, suggesting that C3 modulates the 
inflammatory gene induction that precedes the clinical manifestations. To substantiate this we 
carried out a time-course analysis of the skin gene expression after 3 days of IMQ treatment. 
This showed that in the absence of C3 the resolution of the IMQ-triggered inflammation was 
faster compared to WT mice. Twenty-four hours after the last application, C3-deficient mice 
had significantly reduced levels of all genes analysed, namely IL-1α, TNF-α, IL-17a, IL-23a, 
CXCL1 and CCL2 (Figure S2a). Consistent with this, thickening of the skin assessed by 
histology was significantly reduced in the C3-/- mice (Figure 2b-c). Interestingly, the altered 
skin pathology in the IMQ-treated C3-deficient mice appeared to affect mainly the epidermis. 
Untreated skin of WT and C3-/- mice was histologically indistinguishable. 
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In summary, we demonstrate that C3 is involved in the development and resolution of the 
psoriasiform skin inflammation induced by short-term treatment with IMQ. The pro-
inflammatory effect of C3 is likely to be mediated by several mechanisms. In the absence of 
C3 the expression of psoriasis-relevant genes in the skin was impaired, neutrophil infiltration 
into the inflamed site was decreased and IL-17 production by γδ T cells in the skin and the 
draining LNs was reduced. Taken together these data support a pro-inflammatory role of C3 
during psoriasis-like skin inflammation. 
 
 
CONFLICT OF INTEREST 
The authors declare no conflict of interest 
 
ACKNOWLEGMENTS  
We thank the staff of the Biological Services Unit at our institution for the care of the animals 
involved in this study.  This work was supported by the Wellcome Trust (Grant reference 
number: 108008/Z/15/Z). CG was supported by a Wellcome Trust Institutional strategic 
Support fund (ISSF) Inflammation Science PhD studentship and NB by a studentship from 
Majlis Amanah Rakyat (MARA)  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
REFERENCES 
 
Chehoud C, Rafail S, Tyldsley AS, Seykora JT, Lambris JD, Grice E a. Complement 
modulates the cutaneous microbiome and inflammatory milieu. Proc Natl Acad Sci U S 
A. 2013 Sep 10;110(37):15061–6.  
van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-
induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J 
Immunol. 2009 May 1;182(9):5836–45.  
Hammerberg C, Katiyar SK, Carroll MC, Cooper KD. Activated Complement Component 3 
(C3) Is Required for Ultraviolet Induction of Immunosuppression and Antigenic 
Tolerance. Vol. 187, J ExpMed. 1998 Apr 6; 187(7): 1133-1138. 
Kotnik V, Acta Dermatoven A, Vol APA. Complement in skin diseases. 2011;3–11 
Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind 
the scenes into the spotlight. Am J Pathol. 2007 Sep;171(3):715–27.  
Di Meglio P, Duarte JH, Ahlfors H, Owens NDL, Li Y, Villanova F, Tosi I, Hirota K, Nestle 
FO, Mrowietz U, Gilchrist MJ, Stockinger B. Activation of the aryl hydrocarbon 
receptor dampens the severity of inflammatory skin conditions. Immunity 2014 Jun 19; 
40(6): 989-1001.  
Mrowietz U, Koch W a, Zhu K, Wiedow O, Bartels J, Christophers E, et al. Psoriasis scales 
contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells. Exp 
Dermatol. 2001 Aug;10(4):238–45.  
Pasch MC, Van Den Bosch NH, Daha MR, Bos JD, Asghar SS. Synthesis of complement 
components C3 and factor B in human keratinocytes is differentially regulated by 
cytokines. J Invest Dermatol. 2000 Jan;114(1):78–82.  
Purwar R, Bäumer W, Niebuhr M, Tschernig T, Kietzmann M, Werfel T. A protective role of 
complement component 3 in T cell-mediated skin inflammation. Exp Dermatol. 2011 
Sep;20(9):709–14.  
Rafail S, Kourtzelis I, Foukas PG, Markiewski MM, DeAngelis RA, Guariento M, et al. 
Complement Deficiency Promotes Cutaneous Wound Healing in Mice. J Immunol. 2014 
Dec 29;194(3):1285–91.  
Schonthaler HB, Guinea-Viniegra J, Wculek SK, Ruppen I, Ximénez-Embún P, Guío-
Carrión A, et al. S100A8-S100A9 protein complex mediates psoriasis by regulating the 
expression of complement factor C3. Immunity. 2013 Dec 12;39(6):1171–81.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Scott D, Botto M. The paradoxical roles of C1q and C3 in autoimmunity. Immunobiology. 
2016 Jun; 221(6):719-25 
Takematsu H, Ohkohchi K, Tagami H. Demonstration of anaphylatoxins C3a, C4a and C5a 
in the scales of psoriasis and inflammatory pustular dermatoses. Br J Dermatol. 1986 
Jan;114(1):1–6.  
Tortola L, Rosenwald E, Abel B, Blumberg H, Schäfer M, Coyle AJ, et al. Psoriasiform 
dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest. 2012 
Nov 1;122(11):3965–76.  
Walter A, Schäfer M, Cecconi V, Matter C, Urosevic-Maiwald M, Belloni B, et al. Aldara 
activates TLR7-independent immune defence. Nat Commun. 2013 Jan;4:1560.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
FIGURE LEGENDS 
 
Figure 1. IMQ-induced skin inflammation and psoriasiform dermatitis is 
impaired in C3-deficient mice. 
IMQ was applied for 7 days to the ear of BALB/c WT (black square) and BALB/c.C3-/- (red 
circle) mice. (a) C3 expression in whole skin quantified by qRT-PCR 24 hrs after the last 
application (n=4). Naïve=untreated mice, mean ± SEM relative to cyclophilin, unpaired t test. 
(b) Representative pictures of IMQ-treated ears at day 7. (c) Ear thickness (mean ± SEM) and 
clinical scores (mean ± SD) for erythema and scaling. Representative experiment of two, 
Mann-Whitney test. (d) Number of CD45+ cells, neutrophils (Ly-6G+), monocytes 
(CD11b+Ly-6C+Ly-6G-) and γδ T cells (CD4-CD3+γδ TCR+) at day 7.  (e-f) Proportion of IL-
17+ γδ T cells from skin (e) and LN (f) following in vitro restimulation. Mean ± SEM, 
unpaired t test, *p <0.05, **p <0.01, ***p <0.01. 
 
 
 
 
Figure 2. Reduced early pro-inflammatory response and skin thickening in IMQ-
treated C3-deficient mice. 
(a) IMQ was applied for 3 or 7 days to the ear of BALB/c WT (black square) and 
BALB/c.C3-/- (red circle) mice. Gene expression was analysed in whole skin 24 hrs after the 
last IMQ exposure (n=3-5/group). Naïve=untreated mice, mean ± SEM relative to the control 
gene cyclophilin (SYBR Green assay) or GADPH (Taqman assay) levels. (b) Representative 
images showing H&E staining of cross-sectional ear skin from BALB/c and BALB/c.C3-/- 
mice untreated and 48 hrs after the 3rd IMQ application. The epidermis/dermis boundaries are 
indicated. Scale bars represent 50 µM. (c) Quantification of whole skin and epidermal 
thickness calculated using Image J software. Each symbol represents an individual mouse 
(n=4). Mean ± SEM; unpaired t test; ns=non-significant; *p <0.05, **p <0.01  
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